Human Umbilical Vein Endothelial Cells (HUVEC) Market
Human Umbilical Vein Endothelial Cells (HUVEC) Market Analysis By Type (Single Donors, Pooled Donors), By Application (Wound Healing, Angiogenesis, Oncology, Tissue Engineering), By Region - Global Insights 2021 to 2031
Analysis of Human Umbilical Vein Endothelial Cells (HUVEC) market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Key Questions Answered in Report
-
Which is the most promising application area for human umbilical vein endothelial cells (HUVEC)?
According to Fact.MR, the oncology segment is anticipated to accrue highly lucrative gains to the human umbilical vein endothelial cells (HUVEC) market, attributed to their purported effectiveness in targeting malignant growth. Simultaneously, uptake across tissue culture is also likely to widen in the future.
-
Which countries are likely to offering promising expansion prospects for HUVEC through 2031?
The U.S. and Indian markets are expected to provide immense growth opportunities for HUVEC, as both countries are making significant strides in furthering good quality healthcare across key domains as CVD and cancer treatment.
-
Which prominent players are operating within the global HUVEC landscape?
Some of the prominent players involved in human umbilical vein epithelial cells include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Human Umbilical Vein Endothelial Cells 2016 to 2020 Trends Vs Projections for 2021 to 2031
From 2016 to 2020, demand for human umbilical vein endothelial cell-based treatment has been gradually gaining momentum, as advancements in genetic engineering and biotechnology become increasingly overt. Extensive applications are being witnessed in the oncology domain, followed by tissue culture and angiogenesis.
Growth of the market remained consistent across the COVID-19 pandemic, although initial shocks were experienced in the first half of 2020, attributed to reduced hospital visits amid fears of contracting the novel coronavirus infection. Future prospects are extremely lucrative, especially across emerging economies across Asia as spending on healthcare infrastructure augments.
How is Surging Tissue Engineering Popularity Augmenting Adoption of Human Umbilical Vein Endothelial Cells?
Over the years, tissue engineering has acquired immense popularity, being deployed across a broad spectrum of treatment domains. Tissue engineering provides alternatives to surgical reconstruction, transplants, and other mechanical devices that are used to repair damaged tissues.
The market for tissue engineering is also driven by a continuous increase in the need for effective regenerative treatments owing to a rise in the prevalence of diabetes, obesity, and other disorders due to lifestyle changes, aging population, and growing trauma cases. Hence, demand for human umbilical vein endothelial cells based treatment is garnering significant momentum.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What is the Scope of HUVEC in Angiogenesis?
Angiogenesis using human umbilical vein endothelial cells is proving highly beneficial to address hepatocellular carcinoma (HCC), a typical hyper-vascular tumour. Hepatocellular carcinoma is a debilitating form of liver cancer which typically arises post a severe Hepatitis B or C infection.
Hence, prominent healthcare providers are leveraging advanced treatment and diagnosis approaches to address this condition. Hepatocellular carcinoma is an aggressive malignancy, resulting as the third cause of death by cancer each year. The management of patients with HCC is complex, as both the tumour stage and any underlying liver disease must be considered conjointly.
Country-wise Analysis
How Bright are HUVEC Growth Prospects across the U.S.?
HUVEC-based treatment adoption rate in the U.S. is expanding rapidly to treat cardiovascular diseases. Several studies have established that HUVECs are a highly useful model for research on human endothelium, and is effective in examining the pathophysiological mechanisms involved in the onset of CVDs.
Additionally, this approach is being increasingly incorporated in the diagnosis and treatment of various forms of cancers. Furthermore, these cells are also being incorporated in angiogenesis to study ovulation, inflammation and tumour growth patterns.
Why is India Considered a Lucrative Market for HUVEC Players?
In recent years, India has generated a fertile space for cell culture- and tissue culture-based treatment. As biotechnology acquires rapid pace in the country, numerous initiatives are being undertaken to further its applications across the broad spectrum of treatment areas.
As per data published by India Against Cancer, around 2.25 million people are afflicted with the disease, with new patients amounting to over a million every year. Hence, major companies are accelerating efforts to discover potent treatments, elevating prospects for HUVEC based treatment.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
How are Pooled Donor HUVECs Generating Demand?
By type, pooled donor HUVECs are acquiring significant popularity, and the segment is projected to expand at more than 10% CAGR through 2031, attributed to their ability to reduce donor variability so as to provide a uniform and consistent application standard to key genetic research platforms.
Players such as Lonza offer a series of cryopreserved HUVECs, shipped as frozen primaries, which are pooled donor and single donor based. Their XL size consists of 10 million cells/ampoule which are achieved by pooling donors.
Which is the Primary Application Area of HUVECs?
HUVECs for oncology and cancer treatment are expected to find immense applications over the decade, with the segment expected to surge ahead at 12%-15% CAGR, as prominent healthcare settings leverage the latest cell technology to eradicate the disease.
For instance, HUVEC-docetaxel (DOC) treatment has been proven to make significant breakthroughs with respect to breast cancer treatment, exhibiting more favourable anti-EMT-6 breast cancer effects in vivo.
Competitive Landscape
The HUVEC landscape appears highly consolidated, marked by the presence of a handful of service providers across prominent geographies. These players primarily concentrate on offering high-grade product offerings as their primary expansion strategy.
- In December 2020, Corning Inc. launched the Corning® X-SERIES® cell processing platform which delivers fast, sterile, automated and efficient processing of human blood and blood products to obtain purified populations of immune cells for gene therapy applications
- Thermo Fisher Scientific offers the GibcoTM HUVEC Adherent Cell Culture which is cryopreserved and tested for Hepatitis B (HBV), Hepatitis C (HCV), sterility testing (bacterial & fungi), mycoplasma, HIV-1 and as a growth performance assay
*This list is indicative- full details about prominent human umbilical endothelial cells providers is available upon request.
Report Scope
| Attribute | Details |
|---|---|
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Market Analysis | US$ Mn for Value & ‘000 Units for Volume |
| Key Regions Covered | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Key Countries Covered | U.S., Canada, Germany, France, U.K, Italy, Russia, Nordics, China, Japan, South Korea, India, Australia, Mexico, Brazil, GCC, Turkey |
| Key Segments Covered | Type, Application, Region |
| Key Companies Profiled | Lonza Group AG; PromoCell- Human Centered Science; Merck & Co. KGaA; Thermo Fisher Scientific; Lifeline; Corning Inc. |
| Pricing | Available upon Request |
Key Market Segments Covered
-
By Type :
- Single Donors of Human Umbilical Vein Endothelial Cells
- Pooled Donors of Human Umbilical Vein Endothelial Cells
-
By Application :
- Human Umbilical Vein Endothelial Cells for Wound Healing
- Human Umbilical Vein Endothelial Cells for Angiogenesis
- Human Umbilical Vein Endothelial Cells for Tissue Engineering
- Human Umbilical Vein Endothelial Cells for Inflammation Treatment
- Human Umbilical Vein Endothelial Cells for Oncology
- Human Umbilical Vein Endothelial Cells for Other Applications
-
Region :
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Russia
- Nordics
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- GCC
- Turkey
- Rest of MEA
- North America
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Market Background
- 6. Global Market Volume (Units) Analysis 2016 to 2020 and Forecast, 2021 to 2031
- 7. Global Market - Pricing Analysis
- 8. Global Market Value Analysis 2016 to 2020 and Forecast, 2021 to 2031
- 9. Global Market Analysis 2016 to 2020 and Forecast 2021 to 2031, by Type
- 9.1. Single Donors
- 9.2. Pooled Donors
- 10. Global Market Analysis 2016 to 2020 and Forecast 2021 to 2031, by Application
- 10.1. Wound Healing
- 10.2. Angiogenesis
- 10.3. Tissue Engineering
- 10.4. Inflammation
- 10.5. Oncology
- 10.6. Others
- 11. Global Market Analysis 2016 to 2020 and Forecast 2021 to 2031, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Europe
- 11.4. East Asia
- 11.5. South Asia
- 11.6. Oceania
- 11.7. Middle East and Africa (MEA)
- 12. North America Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 13. Latin America Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 14. Europe Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 15. South Asia Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 16. East Asia Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 17. Oceania Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 18. Middle East and Africa Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 19. Key and Emerging Countries Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 20. Market Structure Analysis
- 21. Competition Analysis
- 21.1. Lonza Group AG
- 21.2. PromoCell- Human Centered Science
- 21.3. Merck & Co. KGaA
- 21.4. Thermo Fisher Scientific
- 21.5. Lifeline
- 21.6. Corning Inc.
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Application
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Application
Table 08: Latin America Market Value (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Application
Table 11: Europe Market Value (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Application
Table 14: South Asia Market Value (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Application
Table 17: East Asia Market Value (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Application
Table 20: Oceania Market Value (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Application
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Type
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2016 to 2031, By Application
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2016 to 2020
Figure 02: Global Market Volume Forecast (in 000' Units), 2021 to 2031
Figure 03: Pricing Analysis (US$) Per Product, By Region, 2020
Figure 04: Pricing Analysis (US$) Per Product, By Region, 2020
Figure 05: Global Market Value Analysis (US$ Mn), 2016 to 2020
Figure 06: Global Market Value Forecast (US$ Mn), 2021 to 2031
Figure 07: Global Market Absolute $ Opportunity, 2021 to 2031
Figure 08: Global Market Share Analysis (%), By Type, 2021 to 2031
Figure 09: Global Market Y-o-Y Analysis (%), By Type, 2021 to 2031
Figure 10: Global Market Attractiveness Analysis by Type, 2021 to 2031
Figure 11: Global Market Share Analysis (%), By Application, 2021 to 2031
Figure 12: Global Market Y-o-Y Analysis (%), By Application, 2021 to 2031
Figure 13: Global Market Attractiveness Analysis by Application, 2021 to 2031
Figure 14: Global Market Share Analysis (%), By Region, 2021 to 2031
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2021 to 2031
Figure 16: Global Market Attractiveness Analysis by Region, 2021 to 2031
Figure 17: North America Market Value Share, By Type, 2021 (E)
Figure 18: North America Market Value Share, By Application, 2021 (E)
Figure 19: North America Market Value Share, By Country, 2021 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2016 to 2020
Figure 21: North America Market Value Forecast (US$ Mn), 2021 to 2031
Figure 22: North America Market Attractiveness Analysis by Type, 2021 to 2031
Figure 23: North America Market Attractiveness Analysis by Application, 2021 to 2031
Figure 24: North America Market Attractiveness Analysis by Country, 2021 to 2031
Figure 25: Latin America Market Value Share, By Type, 2021 (E)
Figure 26: Latin America Market Value Share, By Application, 2021 (E)
Figure 27: Latin America Market Value Share, By Country, 2021 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2016 to 2020
Figure 29: Latin America Market Value Forecast (US$ Mn), 2021 to 2031
Figure 30: Latin America Market Attractiveness Analysis by Type, 2021 to 2031
Figure 31: Latin America Market Attractiveness Analysis by Application, 2021 to 2031
Figure 32: Latin America Market Attractiveness Analysis by Country, 2021 to 2031
Figure 33: Europe Market Value Share, By Type, 2021 (E)
Figure 34: Europe Market Value Share, By Application, 2021 (E)
Figure 35: Europe Market Value Share, By Country, 2021 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2016 to 2020
Figure 37: Europe Market Value Forecast (US$ Mn), 2021 to 2031
Figure 38: Europe Market Attractiveness Analysis by Type, 2021 to 2031
Figure 39: Europe Market Attractiveness Analysis by Application, 2021 to 2031
Figure 40: Europe Market Attractiveness Analysis by Country, 2021 to 2031
Figure 41: South Asia Market Value Share, By Type, 2021 (E)
Figure 42: South Asia Market Value Share, By Application, 2021 (E)
Figure 43: South Asia Market Value Share, By Country, 2021 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2016 to 2020
Figure 45: South Asia Market Value Forecast (US$ Mn), 2021 to 2031
Figure 46: South Asia Market Attractiveness Analysis by Type, 2021 to 2031
Figure 47: South Asia Market Attractiveness Analysis by Application, 2021 to 2031
Figure 48: South Asia Market Attractiveness Analysis by Country, 2021 to 2031
Figure 49: East Asia Market Value Share, By Type, 2021 (E)
Figure 50: East Asia Market Value Share, By Application, 2021 (E)
Figure 51: East Asia Market Value Share, By Country, 2021 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2016 to 2020
Figure 53: East Asia Market Value Forecast (US$ Mn), 2021 to 2031
Figure 54: East Asia Market Attractiveness Analysis by Type, 2021 to 2031
Figure 55: East Asia Market Attractiveness Analysis by Application, 2021 to 2031
Figure 56: East Asia Market Attractiveness Analysis by Country, 2021 to 2031
Figure 57: Oceania Market Value Share, By Type, 2021 (E)
Figure 58: Oceania Market Value Share, By Application, 2021 (E)
Figure 59: Oceania Market Value Share, By Country, 2021 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2016 to 2020
Figure 61: Oceania Market Value Forecast (US$ Mn), 2021 to 2031
Figure 62: Oceania Market Attractiveness Analysis by Type, 2021 to 2031
Figure 63: Oceania Market Attractiveness Analysis by Application, 2021 to 2031
Figure 64: Oceania Market Attractiveness Analysis by Country, 2021 to 2031
Figure 65: Middle East and Africa Market Value Share, By Type, 2021 (E)
Figure 66: Middle East and Africa Market Value Share, By Application, 2021 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2021 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2016 to 2020
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2021 to 2031
Figure 70: Middle East and Africa Market Attractiveness Analysis by Type, 2021 to 2031
Figure 71: Middle East and Africa Market Attractiveness Analysis by Application, 2021 to 2031
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2021 to 2031
Figure 73: U. S. Market Value Analysis (US$ Mn), 2021 & 2031
Figure 74: U. S. Market Value Share, By Type, 2021 (E)
Figure 75: U. S. Market Value Share, By Application, 2021 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2021 & 2031
Figure 77: Canada Market Value Share, By Type, 2021 (E)
Figure 78: Canada Market Value Share, By Application, 2021 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2021 & 2031
Figure 80: Mexico Market Value Share, By Type, 2021 (E)
Figure 81: Mexico Market Value Share, By Application, 2021 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2021 & 2031
Figure 83: Brazil Market Value Share, By Type, 2021 (E)
Figure 84: Brazil Market Value Share, By Application, 2021 (E)
Figure 85: U. K. Market Value Analysis (US$ Mn), 2021 & 2031
Figure 86: U. K. Market Value Share, By Type, 2021 (E)
Figure 87: U. K. Market Value Share, By Application, 2021 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2021 & 2031
Figure 89: Germany Market Value Share, By Type, 2021 (E)
Figure 90: Germany Market Value Share, By Application, 2021 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2021 & 2031
Figure 92: France Market Value Share, By Type, 2021 (E)
Figure 93: France Market Value Share, By Application, 2021 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2021 & 2031
Figure 95: Italy Market Value Share, By Type, 2021 (E)
Figure 96: Italy Market Value Share, By Application, 2021 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2021 & 2031
Figure 98: Spain Market Value Share, By Type, 2021 (E)
Figure 99: Spain Market Value Share, By Application, 2021 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2021 & 2031
Figure 101: Russia Market Value Share, By Type, 2021 (E)
Figure 102: Russia Market Value Share, By Application, 2021 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2021 & 2031
Figure 104: China Market Value Share, By Type, 2021 (E)
Figure 105: China Market Value Share, By Application, 2021 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2021 & 2031
Figure 107: Japan Market Value Share, By Type, 2021 (E)
Figure 108: Japan Market Value Share, By Application, 2021 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2021 & 2031
Figure 110: South Korea Market Value Share, By Type, 2021 (E)
Figure 111: South Korea Market Value Share, By Application, 2021 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2021 & 2031
Figure 113: India Market Value Share, By Type, 2021 (E)
Figure 114: India Market Value Share, By Application, 2021 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2021 & 2031
Figure 116: ASEAN Market Value Share, By Type, 2021 (E)
Figure 117: ASEAN Market Value Share, By Application, 2021 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2021 & 2031
Figure 119: Australia Market Value Share, By Type, 2021 (E)
Figure 120: Australia Market Value Share, By Application, 2021 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2021 & 2031
Figure 122: New Zealand Market Value Share, By Type, 2021 (E)
Figure 123: New Zealand Market Value Share, By Application, 2021 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2021 & 2031
Figure 125: GCC Countries Market Value Share, By Type, 2021 (E)
Figure 126: GCC Countries Market Value Share, By Application, 2021 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2021 & 2031
Figure 128: Turkey Market Value Share, By Type, 2021 (E)
Figure 129: Turkey Market Value Share, By Application, 2021 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2021 & 2031
Figure 131: South Africa Market Value Share, By Type, 2021 (E)
Figure 132: South Africa Market Value Share, By Application, 2021 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How fast is the human umbilical vein endothelial cells (HUVEC) market projected to expand from 2021 to 2031?
According to Fact.MR, the human umbilical vein endothelial cells market is projected to surge ahead at approx. 10% CAGR through 2031, with the growth rate even higher in Western countries as compared to other parts of the world.
Which is the most promising application area for human umbilical vein endothelial cells (HUVEC)?
The oncology segment is anticipated to accrue highly lucrative gains to the human umbilical vein endothelial cells (HUVEC) market, expanding at close to 15% CAGR over the next ten years, attributed to their purported effectiveness in targeting malignant g
Which countries are likely to offering promising expansion prospects for HUVEC through 2031?
North America, especially the U.S., and Europe, are expected to account for more than 40% market share, and are expected to provide immense growth opportunities for HUVEC, as both regions are making significant strides in furthering good quality healthcar
Which prominent players are operating within the global HUVEC landscape?
Some of the prominent players involved in human umbilical vein epithelial cells include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc.
Human Umbilical Vein Endothelial Cells (HUVEC) Market